Perioperative Nivolumab in Resectable Lung Cancer

NEJM #LungCancer #Meded #medx #Oncology OncoAlert OncoDaily #Nivolumab

nejm.org/doi/full/10.10…

Perioperative nivolumab for resectable NSCLC improves 18-month event-free survival to 70.2% vs. 50.0% with chemo and achieves a 25.3% pathological complete response rate. #LungCancer #Immunotherapy #NSCLC NEJM OncoAlert

T:👉Immunoterapinin ameliyat öncesi ve sonrası eklenmesinin akciğer kanserindeki faydası yeni faz 3 çalışmasıyla doğrulandı. NEJM makalesi*

Evre IIA'dan IIIB'ye kadar ameliyat edilebilen küçük hücreli olmayan akciğer kanseri (KHDAK) olan yetişkinlerde nivolumab artı kemoterapi

Ipilimumab is done, nivolumab going now 👍

T:👉Nature Medicine dergisinde yayınlanan yeni makale,* devam eden bir faz 2 çalışmasında, tedavi görmemiş 60 ameliyat edilebilir küçük hücreli dışı akciğer kanseri hastasında, nivolumab (anti-PD-1 antikoru) tek başına veya relatlimab (anti-LAG-3 antikoru) ile birlikte test

In a randomized trial of perioperative nivolumab as compared with chemotherapy, 18-month event-free survival was 70% in the nivolumab group and 50% in the chemotherapy group at 2-year median follow-up. Read the full CheckMate 77T phase 3 trial results: nej.md/3VaMtbX

Pictures always help!

Just how good is $CRVS interim data for its Phase 2 #A2AR antagonist #Ciforadenant data in combo w/ #Nivolumab + #Ipilimumab ? Really good!
It is at least a 48% deep response rate, which means even higher! Market is not pricing this
nejm.org/doi/full/10.10…

#A2AR antagonists 'Next Generation Checkpoint Blockade for Cancer Immunotherapy' right combo been elusive, until now!

$CRVS combo #Ciforadenant + anti-PD-1 #nivolumab + anti-CTLA-4 #ipilimumab in front-line #RCC >50% more deep responses!

Checkpoint inhibitors growing to $189B!

First-Line Nivolumab/Ipilimumab Improves Survival in Hepatocellular Cancer vist.ly/zkje #livercancer news #livercancer #liverdisease #researchstudy

Results of #Checkmate 77T trial are out..
#Perioperative #Nivolumab (neoadjuvant nivo + chemo followed by surgery followed by adj. nivo) in stage IIA-IIIB #NSCLC showing:

⬆️ #DFS & ⬆️ #PCR
And 25% PCR

NEJM OncoAlert Oncology Brothers
iasmintira
#lungcancer

nej.md/3VaMtbX

Checkmate 77T. Perioperative Nivolumab in early stage resectable NSCLC. EFS benifit as per Stage and PDL1 expression. Subsequent therapies for both arms . How much additional benifit this gives over only neo adjuvant nivo . We don't know. NEJM

Frontline Nivolumab + Relatlimab (LAG3) in Gastric/GEJ a miss in RELATIVITY-060
❌Nivo + Rela + Chemo: PFS 7M | OS 13.5M
❌Nivo + Chemo : PFS 8.3M | OS 16M+
TIGIT > LAG3 for GEJ based on SKYSCRAPER-08?
ascopubs.org/doi/10.1200/JC…

In this trial, although first-line cohort 1 treatment improved objective response rates, considerable progression events urge caution with this as a first-line therapy. Second-/third-line cohort 1 treatment did not improve response rates compared with nivolumab monotherapy.

💉Adding relatlimab to nivolumab+ ChT in first line treatment of advanced gastric and GEJ cancer
RELATIVITY-060 Journal of Clinical Oncology

❌Negative study
➡️ORR: 48% vs 61%
➡️mPFS: 7.0 vs 8.3 mo, HR: 1.41 (0.97 to 2.05)
➡️mOS: 13.5 vs 16.0 mo, HR, 1.04: (0.70 to 1.54)

The NEOpredict-Lung study represents an important🤓evolution in the treatment of resectable NSCLC🫁, evaluating the feasibility and safety of preoperative combined treatment of nivolumab and relatlimab. The selection of this therapeutic approach was based on the premise that

Adjuvant Nivolumab finally shows OS benifit in MIUC . Checkmate274 . #EAU24 . adjuvant Pembrolizumab did not in Ambassador . Again why one IO works and other does not ? I don't know . Any one ? What to give these pts on progression after adjuvant Nivo ? Vinay Prasad MD MPH

44 months extended follow up of checkmate 9ER trial for advanced RCC . Maximum benifit in poor risk category. No OS benifit in favorable risk category. Intresting to note subsequent therapies in those who completed 2 years of Nivolumab. ESMO - Eur. Oncology Tom Powles

Terrific work! You have been so dedicated to the KIM-1 story, including your recent terrific poster at AACR describing the biomarker in the adjuvant setting via #CM914 ( #nivolumab / #ipilimumab in high-risk localized #kidneycancer ). Proud of you for leading this large at important

Immunotherapy before and after Surgery Improves Survival in Lung Cancer Patients

Results from the randomized CheckMate 77T trial showed that nivolumab significantly improved survival in operable NSCLC patients. Learn more: ow.ly/JaAf50RIsn2

Check out our new story out in Nature Medicine today: a phase II study of nivolumab in dMMR/hypermutated gynecologic cancers together with my dear friend Claire Friedman MD . link.springer.com/article/10.103… brief summary (thread):